AR005750A1 - Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion - Google Patents

Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion

Info

Publication number
AR005750A1
AR005750A1 ARP970100494A ARP970100494A AR005750A1 AR 005750 A1 AR005750 A1 AR 005750A1 AR P970100494 A ARP970100494 A AR P970100494A AR P970100494 A ARP970100494 A AR P970100494A AR 005750 A1 AR005750 A1 AR 005750A1
Authority
AR
Argentina
Prior art keywords
zoster
composition
treat
infections
preparing
Prior art date
Application number
ARP970100494A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602617.4A external-priority patent/GB9602617D0/en
Priority claimed from GBGB9626882.6A external-priority patent/GB9626882D0/en
Application filed by Smithkline Beecham Biolog, Univ Liege filed Critical Smithkline Beecham Biolog
Publication of AR005750A1 publication Critical patent/AR005750A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Se refiere a composiciones para el tratamiento o prevención del Zoster de individuos infectados con el virus Varicela Zoster (VZV) y a la prevención ytratamiento de infecciones de varicela. Las composiciones comprenden la proteínacodificad a por el gen 63 de VZV o un derivado inmunológicamenteactivo de la misma. Además se refiere a composiciones que contienen el ADN o ARN correspondiente al gen 63 de VZV. Se propone también el uso de dichaproteína para la elaboración demedicamentos , inclusive vacunas para tratar esas infecciones.
ARP970100494A 1996-02-09 1997-02-07 Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion AR005750A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9602617.4A GB9602617D0 (en) 1996-02-09 1996-02-09 Vaccines
GBGB9626882.6A GB9626882D0 (en) 1996-12-24 1996-12-24 Vaccines

Publications (1)

Publication Number Publication Date
AR005750A1 true AR005750A1 (es) 1999-07-14

Family

ID=26308641

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100494A AR005750A1 (es) 1996-02-09 1997-02-07 Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion

Country Status (20)

Country Link
EP (1) EP0879060B1 (es)
JP (1) JP2002504080A (es)
KR (1) KR100365986B1 (es)
CN (1) CN1210470A (es)
AR (1) AR005750A1 (es)
AT (1) ATE390146T1 (es)
AU (1) AU723555B2 (es)
BR (1) BR9707400A (es)
CA (1) CA2245545C (es)
CZ (1) CZ289971B6 (es)
DE (1) DE69738597T2 (es)
ES (1) ES2301175T3 (es)
HU (1) HUP0001991A3 (es)
IL (1) IL125440A (es)
NO (1) NO983617L (es)
NZ (1) NZ331164A (es)
PL (1) PL188457B1 (es)
TR (1) TR199801531T2 (es)
TW (1) TW575427B (es)
WO (1) WO1997028820A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
BR9908599A (pt) * 1998-03-09 2000-11-14 Smithkline Beecham Biolog Composições combinadas de vacina
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
PT1227840E (pt) * 1999-11-03 2008-01-09 Powderject Vaccines Inc Vacinas genéticas adjuvadas
IL151097A0 (en) * 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
EA020617B1 (ru) 2009-05-27 2014-12-30 Глаксосмитклайн Байолоджикалс С.А. Конструкции casb7439
KR101723605B1 (ko) * 2014-10-21 2017-04-07 진원생명과학 주식회사 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법
CN114891830B (zh) * 2022-04-02 2024-03-01 武汉博沃生物科技有限公司 基于水痘-带状疱疹病毒的重组表达载体、重组病毒及用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952674A (en) * 1986-05-02 1990-08-28 Merck & Co., Inc. Vaccine against varicella-zoster virus
ES2071770T3 (es) * 1989-06-27 1995-07-01 Smithkline Beecham Biolog Nuevos compuestos.

Also Published As

Publication number Publication date
KR100365986B1 (ko) 2003-02-20
EP0879060A1 (en) 1998-11-25
KR19990082360A (ko) 1999-11-25
TW575427B (en) 2004-02-11
NO983617D0 (no) 1998-08-06
ATE390146T1 (de) 2008-04-15
CA2245545A1 (en) 1997-08-14
IL125440A0 (en) 1999-03-12
DE69738597T2 (de) 2008-07-24
WO1997028820A1 (en) 1997-08-14
PL328414A1 (en) 1999-01-18
TR199801531T2 (xx) 1998-10-21
HUP0001991A2 (hu) 2000-10-28
PL188457B1 (pl) 2005-02-28
CZ248698A3 (cs) 1998-12-16
NZ331164A (en) 2000-02-28
BR9707400A (pt) 2000-01-04
JP2002504080A (ja) 2002-02-05
EP0879060B1 (en) 2008-03-26
CA2245545C (en) 2008-12-30
ES2301175T3 (es) 2008-06-16
CN1210470A (zh) 1999-03-10
NO983617L (no) 1998-10-02
AU1601297A (en) 1997-08-28
DE69738597D1 (de) 2008-05-08
HUP0001991A3 (en) 2003-08-28
IL125440A (en) 2002-02-10
CZ289971B6 (cs) 2002-05-15
AU723555B2 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
BR9810745A (pt) Derivados de benzimidazol
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
ATE138384T1 (de) Olionukleotidalkylphosphonate und - phosphonothioate
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
DE69131200T2 (de) Herpes simplex virus vp16 impfstoffe
BR9712366A (pt) Gene de gd2 do vírus do herpes simples hsv2 isolado, plasmídeo compreendendo o mesmo, e, processos de induzir, em indivíduo, uma resposta imune contra hsv2 gd2, de tratar um indíviduo que está infectado com hsv, e, de prevenir que um indivíduo fique infectado com hsv
CA2111580A1 (fr) Composes immunogenes a effet notamment anti-cytokine, procede de preparation, compositions pharmaceutiques et kits les renfermant
ATE306938T1 (de) Verwendung von cpg als adjuvans für hivimpstoff
ES2151506T3 (es) Moleculas de adn recombinante que codifican enzimas aminopeptidasa y su uso en la preparacion de vacunas contra infecciones por helmintos.
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
BR0316291A (pt) Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
ES2141093T3 (es) Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas.
MX9805441A (es) Compuestos terapeuticos.
BR0206112A (pt) Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina
BR9508629A (pt) Composto solvato e hidrato do mesmo processos para o tratamento ou profilaxia de uma infecção viral num ser humano e para a preparação do composto uso de um composto e formulação farmacêutica
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
ES2171450T3 (es) Adn de bajo peso molecular procedente de lecha de esturion, procedimiento para obtener el adn y preparacion farmaceutica basada en el mismo.
ES2182827T3 (es) Gen del virus corona canino y usos del mismo.
ES2147200T3 (es) Uso de un veneno de himenopteros para la fabricacion de un medicamento para tratar infecciones por virus de adn.
MX9401370A (es) Terapia antiviral.
GR3032621T3 (en) Extracts of piliostigma thonningii, the use thereof and formulations containing them.
ES2062266T3 (es) Uso de quinolil- e isoquinoliloxazol-2-onas para la obtencion de un medicamento destinado para la prevencion de infecciones por virus envueltos por glicoproteinas.
BR9708720A (pt) Composição farmacêutica e processo para o tratamento de demência por hiv.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal